Technology Transfer Entrepreneurship

See how three successful professors got involved with entrepreneurship on campus and the resources they used to start their companies.

1:00 - 2:30 p.m. Stamp Student Union, Juan Ramón Jiménez Room

UM Panel Members:

Dr. Phil DeShong
Professor, Chemistry & Biochemistry
Founder and CTO, SD Nanosciences, Inc.

Dr. Steven Hutcheson
Professor, Cell Biology & Molecular Genetics
Founder, CEO and President, Zymetis, Inc.

Dr. David Mosser
Professor, Cell Biology & Molecular Genetics
Director, Maryland Pathogen Research Institute
Founder and CEO, LeukoSight Inc.

Moderator:
Jim Chung
Director, Venture Accelerator Program, MTECH

Philip DeShong, PhD, is a professor in the Department of Chemistry & Biochemistry, University of Maryland. Dr. DeShong’s research focuses on the development of new synthetic methods, the total synthesis of biologically active substances, and the application of functionalized nanomaterials for use as diagnostic and drug delivery agents. He is also a member of the Bioengineering program and the Nanomedicine Center at the University of Maryland Medical School. Along with Daniel Stein and Terry Chase, DeShong is a co-founder of SD Nanosciences, Inc. Dr. DeShong received his BS at the University of Texas, Austin, his ScD at MIT, and performed postdoctoral studies at the Swiss Federal Institute of Technology and MIT.

Steven W. Hutcheson, PhD, is a Professor in the Department of Cell Biology & Molecular Genetics at the University of Maryland. He received his PhD from the University of California, Berkeley. His research examines the role and regulation of type III protein secretion in the pathogenicity of Pseudomonas syringae and the degradative abilities of Microbulbifer degradans, a marine bacterium isolated from diseased salt marsh grass in the Chesapeake Bay. He is also the founder, CEO and President of Zymetis, Inc., a biotechnology company dedicated to developing novel enzyme products derived from unique organisms to achieve lower costs, improved yields and higher manufacturing efficiencies in the conversion of cellulosic biomass into a useable energy product (bioethanol).

David M. Mosser, PhD, is a professor in the Department of Cell Biology and Molecular Genetics, University of Maryland, and the Founder and CEO of LeukoSight, Inc. He received his PhD from North Carolina State University and did his postdoctoral training at Harvard Medical School. Dr. Mosser is the Director of UM’s Laboratory of Macrophage Biology. A leader in this field, he has studied macrophages and their products for more than 20 years. In May, 2006 he became the Chairman of the Board of Directors of LeukoSight, Inc., a start-up biopharmaceutical company using university faculty-based discoveries to address unmet medical needs in the area of inflammation and autoimmune diseases.